Page 2 - Ryan Bariola News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The Philadelphia Inquirer Star Tribune Vials are inspected at Regeneron Pharmaceutical’s facilities in New York state, for efforts on an experimental coronavirus antibody drug.   TribLIVE's Daily and Weekly email newsletters deliver the news you want and information you need, right to your inbox. PHILADELPHIA — Drugs that can keep high-risk covid-19 patients out of the hospital are going begging because the supposed breakthrough treatments require an hour-long intravenous infusion and offer a rather small chance of benefit. On Monday, Regeneron announced results that may help make its m...

Low Demand For Antibody Drugs Against COVID-19 Update RequiredTo play audio, update browser or Flash plugin. President Trump boards Marine One for a trip from the White House to Walter Reed National Military Medical Center for COVID-19 treatment in early October. Trump received Regeneron's antibody cocktail during his illness. Alex Brandon / AP Federal officials are disappointed to find that the monoclonal antibody drugs they've shipped across the country aren't being used rapidly. These drugs are designed to prevent people recently diagnosed with COVID-19 from ending up in the ...

  / President Trump boards Marine One for a trip from the White House to Walter Reed National Military Medical Center for COVID-19 treatment in early October. Trump received Regeneron's antibody cocktail during his illness. // AP, Alex Brandon Federal officials are disappointed to find that the monoclonal antibody drugs they've shipped across the country aren't being used rapidly. These drugs are designed to prevent people recently diagnosed with COVID-19 from ending up in the hospital. But hospitals are finding it cumbersome to use these medicines, which must be given by IV infusion. ...

Alex Brandon/AP toggle caption Alex Brandon/AP President Trump boards Marine One for a trip from the White House to Walter Reed National Military Medical Center for COVID-19 treatment in early October. Trump received Regeneron's antibody cocktail during his illness. Alex Brandon/AP Federal officials are disappointed to find that the monoclonal antibody drugs they've shipped across the country aren't being used rapidly. These drugs are designed to prevent people recently diagnosed with COVID-19 from ending up in the hospital. But hospitals are finding it...

Low Demand For Antibody Drugs Against COVID-19 Federal officials are disappointed to find that the monoclonal antibody drugs they've shipped across the country aren't being used rapidly. These drugs are designed to prevent people recently diagnosed with COVID-19 from ending up in the hospital. But hospitals are finding it cumbersome to use these medicines, which must be given by IV infusion. And some patients and doctors are lukewarm about drugs that have an uncertain benefit. The Food and Drug Administration granted emergency authorization in November to two monoclonal antibody products â€...